A new drug that increases concentration in the body
endogenous cannabinoid anandamide, aided by heavy marijuana smokers
significantly reduce the daily dose without withdrawal. Results of the second phase
clinical studies published in the journal The lancet psychiatry.
Despite the fact that he smokes marijuana in some countries of the world
In recent years, it has been recognized as a fairly safe practice and received legal
status, the abuse of it can lead to the development of addiction. disorder,
associated with the use of cannabis, it is officially included in the diagnostic guide on the mental
US troubles and includes risky consumption,
social sphere, the development of substance tolerance and when trying to quit – the development of abstinence syndrome. For cannabis syndrome, sleep disorders, irritability,
anxiety, loss of appetite and weight loss, as well as the craving for marijuana.
According to American psychiatrists,
one third of marijuana users in the United States have these symptoms of addiction.
It usually helps to throw or at least reduce the amount of smoked grass
only psychotherapy, since almost all classes of psychotropic drugs in
the tests did not help alleviate the withdrawal syndrome.
cannabis acts on the endocannabinoid system receptors, one of the main ones
natural agonists that in the human body is anandamide. such as
he has shown preliminary experiments by blocking a destroying enzyme
anandamide (FAAH), allows you to increase it
concentration in the blood and alleviate withdrawal symptoms in addicts
tetrahydrocannabinol (THC) mice. For this reason, the FAAH inhibitor
researchers interested in drugs to treat addiction
Phase two clinical trials
has shown that it really helps participants to normalize well-being
with the abolition and consequently reduce the consumption of cannabis.
The study involved 70
men, everyone smoked at least three cigarettes with
marijuana daily and has had signs of associated mental disorder
with consumption. During the first week of the experiment, they were placed in a hospital,
and smoking was forbidden, with the result that the participants had withdrawal symptoms.
In the next three
weeks 46 participants took an FAAH inhibitor –
the drug, codenamed PF-04457845, and the remaining 24 received a placebo.
Experimental reports on the intake of the drug, on the quantity of marijuana smoked e
on your well-being In addition to self-reports, they have measured
concentration of anandamide in the blood and metabolite of THC in the urine. Quality of registered sleep
using polysomnography – a complex test that takes into account the brain
activity, heart rate and respiration, eye and limb movements during sleep.
According to the results of the monthly trial, the researchers concluded
that the drug works – therefore, the sleep quality of the experimental group has improved immediately.
The number of marijuana daily in the experimental group decreased on average to 0.4 cigarettes,
while the placebo group had up to 1.3, which correlated with the laboratory
analysis for THC content. There are no significant side effects.
the drug was not observed.
Despite the encouraging results, before the approval
experts recommend testing it on women and smokers
which have associated mental illnesses that often increase
risk of marijuana addiction
According to WHO, marijuana is the most common in the world.
the drug Employees of about 13 million people in the world
marijuana. However, the legalization of medical marijuana has reduced consumption
opioid drugs by patients and a concomitant level of more serious